Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States

BACKGROUND: Gaucher disease type 1 (GD1) is a rare, genetic, lysosomal storage disease with no cure. Current treatment options include intravenous (IV) enzyme replacement therapy ([ERT]; imiglucerase, velaglucerase alfa, or taliglucerase alfa) or oral substrate reduction therapy ([SRT]; eliglustat o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nalysnyk, Luba, Sugarman, Rebecca, Cele, Clifford, Uyei, Jennifer, Ward, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397643/
https://www.ncbi.nlm.nih.gov/pubmed/30247105
http://dx.doi.org/10.18553/jmcp.2018.24.10.1002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397643/
https://www.ncbi.nlm.nih.gov/pubmed/30247105
http://dx.doi.org/10.18553/jmcp.2018.24.10.1002

Ejemplares similares